Portfolio Design Labs LLC Takes Position in Cardinal Health, Inc. $CAH

Portfolio Design Labs LLC acquired a new position in shares of Cardinal Health, Inc. (NYSE:CAH) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 2,905 shares of the company’s stock, valued at approximately $690,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Kornitzer Capital Management Inc. KS raised its position in Cardinal Health by 100.8% during the 4th quarter. Kornitzer Capital Management Inc. KS now owns 18,164 shares of the company’s stock worth $3,733,000 after purchasing an additional 9,120 shares during the last quarter. Abacus FCF Advisors LLC bought a new stake in shares of Cardinal Health in the 4th quarter valued at about $7,182,000. Byrne Financial Freedom LLC bought a new stake in shares of Cardinal Health in the 4th quarter valued at about $1,574,000. Belleair Asset Management LLC acquired a new stake in shares of Cardinal Health in the fourth quarter valued at about $1,100,000. Finally, Axecap Investments LLC bought a new position in shares of Cardinal Health during the fourth quarter worth about $2,371,000. Institutional investors and hedge funds own 87.17% of the company’s stock.

Key Cardinal Health News

Here are the key news stories impacting Cardinal Health this week:

• Positive Sentiment: Royal Bank of Canada initiated coverage of Cardinal Health with a “moderate buy” or outperform-equivalent rating. RBC cited the integration of higher-margin services as a potential driver of future earnings outperformance. RBC Capital Starts Cardinal Health at Outperform
• Positive Sentiment: A Zacks analysis identified CAH as a potentially attractive long-term value stock, while recent coverage has highlighted Cardinal Health’s precision-medicine operations and higher-margin services as sources of sustained growth. Why Cardinal Health Is a Top Value Stock for the Long-Term
• Neutral Sentiment: Brokerages continue to assign Cardinal Health a consensus “moderate buy” rating. The constructive view is tempered by valuation and questions about the sustainability of recent earnings gains.
• Negative Sentiment: Multiple executives and insiders sold shares around $235–$237. Chief Executive Officer Jason Hollar sold a combined 124,529 shares worth approximately $29.4 million, while CEO Deborah Weitzman sold about $1.7 million. Other insider sales included Chief Accounting Officer Mary Scherer and executives Michelle Greene, Jessica Mayer, and Stephen Mason. The transactions substantially reduced several executives’ holdings and may signal that insiders are taking profits after the stock’s strong rally. Cardinal Health Insider Sale Filing
• Negative Sentiment: Although Cardinal Health reported adjusted quarterly EPS of $2.91, well above the $2.42 consensus, an analysis noted that a significant portion of the earnings improvement came from a one-time tariff refund. That raises concerns about the durability of the earnings beat and may be contributing to the weaker stock performance. Cardinal Health Earnings Analysis

Insider Buying and Selling

In related news, CEO Jason M. Hollar sold 44,529 shares of the company’s stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $236.18, for a total value of $10,516,859.22. Following the sale, the chief executive officer owned 190,603 shares in the company, valued at $45,016,616.54. This represents a 18.94% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CAO Mary C. Scherer sold 2,302 shares of the firm’s stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $237.39, for a total transaction of $546,471.78. Following the completion of the transaction, the chief accounting officer directly owned 2,811 shares in the company, valued at approximately $667,303.29. The trade was a 45.02% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 210,271 shares of company stock worth $49,626,657 over the last ninety days. Insiders own 0.12% of the company’s stock.

Analysts Set New Price Targets

CAH has been the topic of a number of recent analyst reports. Weiss Ratings lowered Cardinal Health from a “buy (b+)” rating to a “buy (b)” rating in a research note on Wednesday. Wells Fargo & Company increased their target price on shares of Cardinal Health from $245.00 to $277.00 and gave the company an “overweight” rating in a research report on Wednesday, August 12th. Zacks Research lowered shares of Cardinal Health from a “strong-buy” rating to a “hold” rating in a report on Friday, June 12th. UBS Group boosted their price target on shares of Cardinal Health from $274.00 to $280.00 and gave the stock a “buy” rating in a research report on Wednesday, August 12th. Finally, Bank of America upped their price objective on shares of Cardinal Health from $240.00 to $260.00 and gave the company a “buy” rating in a research note on Thursday, July 2nd. Sixteen equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, Cardinal Health currently has a consensus rating of “Moderate Buy” and an average price target of $266.56.

Cardinal Health Stock Down 2.5%

Shares of CAH opened at $228.95 on Friday. Cardinal Health, Inc. has a 12-month low of $145.87 and a 12-month high of $258.30. The business’s fifty day moving average is $231.91 and its 200 day moving average is $217.78. The stock has a market cap of $53.25 billion, a P/E ratio of 31.67, a P/E/G ratio of 1.26 and a beta of 0.49.

Cardinal Health (NYSE:CAH) last announced its quarterly earnings results on Tuesday, August 11th. The company reported $2.91 EPS for the quarter, beating analysts’ consensus estimates of $2.42 by $0.49. Cardinal Health had a net margin of 0.67% and a negative return on equity of 98.53%. The business had revenue of $63.67 billion during the quarter, compared to analyst estimates of $65.15 billion. During the same quarter in the previous year, the business posted $2.08 EPS. Cardinal Health’s quarterly revenue was up 5.8% on a year-over-year basis. Cardinal Health has set its FY 2027 guidance at 12.400-12.600 EPS. On average, analysts expect that Cardinal Health, Inc. will post 12.54 EPS for the current year.

Cardinal Health Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Thursday, October 1st will be given a dividend of $0.5158 per share. The ex-dividend date of this dividend is Thursday, October 1st. This represents a $2.06 annualized dividend and a dividend yield of 0.9%. Cardinal Health’s payout ratio is presently 28.49%.

About Cardinal Health

Cardinal Health is a multinational healthcare services and products company headquartered in Dublin, Ohio. Tracing its roots to the early 1970s, the company has grown into a major provider of supply chain and distribution services for the healthcare sector. Cardinal Health operates across a range of service lines that support hospitals, health systems, pharmacies, physician offices and clinical laboratories.

The company’s core activities include the wholesale distribution of branded and generic pharmaceuticals, the supply and distribution of medical-surgical products, and the provision of logistics and inventory management solutions.